UCB SA (UNC.DE) Stock Fundamental Analysis

FRA:UNC • BE0003739530

269.3 EUR
+6.1 (+2.32%)
Last: Feb 12, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

Overall UNC gets a fundamental rating of 6 out of 10. We evaluated UNC against 52 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of UNC get a neutral evaluation. Nothing too spectacular is happening here. UNC is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make UNC suitable for growth investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year UNC was profitable.
  • In the past year UNC had a positive cash flow from operations.
  • In the past 5 years UNC has always been profitable.
  • Each year in the past 5 years UNC had a positive operating cash flow.
UNC.DE Yearly Net Income VS EBIT VS OCF VS FCFUNC.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

1.2 Ratios

  • With a Return On Assets value of 7.75%, UNC perfoms like the industry average, outperforming 57.69% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 13.76%, UNC is in line with its industry, outperforming 55.77% of the companies in the same industry.
  • UNC's Return On Invested Capital of 11.63% is in line compared to the rest of the industry. UNC outperforms 57.69% of its industry peers.
  • UNC had an Average Return On Invested Capital over the past 3 years of 4.35%. This is significantly below the industry average of 14.38%.
  • The last Return On Invested Capital (11.63%) for UNC is above the 3 year average (4.35%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.75%
ROE 13.76%
ROIC 11.63%
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
UNC.DE Yearly ROA, ROE, ROICUNC.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6 8 10

1.3 Margins

  • Looking at the Profit Margin, with a value of 19.45%, UNC is in the better half of the industry, outperforming 73.08% of the companies in the same industry.
  • In the last couple of years the Profit Margin of UNC has remained more or less at the same level.
  • UNC's Operating Margin of 26.58% is fine compared to the rest of the industry. UNC outperforms 63.46% of its industry peers.
  • UNC's Operating Margin has declined in the last couple of years.
  • With a decent Gross Margin value of 73.38%, UNC is doing good in the industry, outperforming 65.38% of the companies in the same industry.
  • In the last couple of years the Gross Margin of UNC has remained more or less at the same level.
Industry RankSector Rank
OM 26.58%
PM (TTM) 19.45%
GM 73.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
UNC.DE Yearly Profit, Operating, Gross MarginsUNC.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so UNC is still creating some value.
  • The number of shares outstanding for UNC remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for UNC has been increased compared to 5 years ago.
  • Compared to 1 year ago, UNC has an improved debt to assets ratio.
UNC.DE Yearly Shares OutstandingUNC.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
UNC.DE Yearly Total Debt VS Total AssetsUNC.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

  • An Altman-Z score of 5.63 indicates that UNC is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 5.63, UNC is doing good in the industry, outperforming 78.85% of the companies in the same industry.
  • The Debt to FCF ratio of UNC is 2.43, which is a good value as it means it would take UNC, 2.43 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of UNC (2.43) is better than 80.77% of its industry peers.
  • UNC has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of UNC (0.29) is better than 69.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 2.43
Altman-Z 5.63
ROIC/WACC1.49
WACC7.82%
UNC.DE Yearly LT Debt VS Equity VS FCFUNC.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.3 Liquidity

  • UNC has a Current Ratio of 1.35. This is a normal value and indicates that UNC is financially healthy and should not expect problems in meeting its short term obligations.
  • UNC's Current ratio of 1.35 is in line compared to the rest of the industry. UNC outperforms 53.85% of its industry peers.
  • A Quick Ratio of 1.01 indicates that UNC should not have too much problems paying its short term obligations.
  • UNC has a Quick ratio (1.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.35
Quick Ratio 1.01
UNC.DE Yearly Current Assets VS Current LiabilitesUNC.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • UNC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.41%, which is quite impressive.
  • The Earnings Per Share has been decreasing by -0.86% on average over the past years.
  • Looking at the last year, UNC shows a very strong growth in Revenue. The Revenue has grown by 25.56%.
  • The Revenue has been growing slightly by 4.60% on average over the past years.
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%

3.2 Future

  • UNC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.00% yearly.
  • Based on estimates for the next years, UNC will show a quite strong growth in Revenue. The Revenue will grow by 15.34% on average per year.
EPS Next Y60.25%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
EPS Next 5Y30%
Revenue Next Year25.37%
Revenue Next 2Y19.85%
Revenue Next 3Y17.72%
Revenue Next 5Y15.34%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
UNC.DE Yearly Revenue VS EstimatesUNC.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B
UNC.DE Yearly EPS VS EstimatesUNC.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20 25

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 41.95, UNC can be considered very expensive at the moment.
  • 61.54% of the companies in the same industry are cheaper than UNC, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of UNC to the average of the S&P500 Index (26.68), we can say UNC is valued expensively.
  • UNC is valuated quite expensively with a Price/Forward Earnings ratio of 26.19.
  • The rest of the industry has a similar Price/Forward Earnings ratio as UNC.
  • UNC is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 41.95
Fwd PE 26.19
UNC.DE Price Earnings VS Forward Price EarningsUNC.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • UNC's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. UNC is more expensive than 61.54% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of UNC is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 44.2
EV/EBITDA 21.52
UNC.DE Per share dataUNC.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • UNC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • UNC has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as UNC's earnings are expected to grow with 38.91% in the coming years.
PEG (NY)0.7
PEG (5Y)N/A
EPS Next 2Y43.7%
EPS Next 3Y38.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.36%, UNC is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 1.89, UNC is paying slightly less dividend.
  • With a Dividend Yield of 0.36, UNC pays less dividend than the S&P500 average, which is at 1.84.
Industry RankSector Rank
Dividend Yield 0.36%

5.2 History

  • The dividend of UNC has a limited annual growth rate of 2.46%.
Dividend Growth(5Y)2.46%
Div Incr YearsN/A
Div Non Decr YearsN/A

5.3 Sustainability

  • UNC pays out 19.82% of its income as dividend. This is a sustainable payout ratio.
  • UNC's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP19.82%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
UNC.DE Yearly Income VS Free CF VS DividendUNC.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
UNC.DE Dividend Payout.UNC.DE Dividend Payout, showing the Payout Ratio.UNC.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

UCB SA

FRA:UNC (2/12/2026, 7:00:00 PM)

269.3

+6.1 (+2.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)02-26
Inst Owners41.62%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap52.38B
Revenue(TTM)6.85B
Net Income(TTM)1.33B
Analysts73.85
Price Target276.11 (2.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.36%
Yearly Dividend1.36
Dividend Growth(5Y)2.46%
DP19.82%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.96%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 41.95
Fwd PE 26.19
P/S 7.65
P/FCF 44.2
P/OCF 33.24
P/B 5.41
P/tB 48.19
EV/EBITDA 21.52
EPS(TTM)6.42
EY2.38%
EPS(NY)10.28
Fwd EY3.82%
FCF(TTM)6.09
FCFY2.26%
OCF(TTM)8.1
OCFY3.01%
SpS35.21
BVpS49.78
TBVpS5.59
PEG (NY)0.7
PEG (5Y)N/A
Graham Number84.8
Profitability
Industry RankSector Rank
ROA 7.75%
ROE 13.76%
ROCE 13.73%
ROIC 11.63%
ROICexc 13.71%
ROICexgc 58.2%
OM 26.58%
PM (TTM) 19.45%
GM 73.38%
FCFM 17.3%
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexgc growth 3Y-25.87%
ROICexgc growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 2.43
Debt/EBITDA 1.15
Cap/Depr 61.48%
Cap/Sales 5.71%
Interest Coverage 16.4
Cash Conversion 64.17%
Profit Quality 88.96%
Current Ratio 1.35
Quick Ratio 1.01
Altman-Z 5.63
F-Score9
WACC7.82%
ROIC/WACC1.49
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)75.41%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%68.9%
EPS Next Y60.25%
EPS Next 2Y43.7%
EPS Next 3Y38.91%
EPS Next 5Y30%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%24.94%
Revenue Next Year25.37%
Revenue Next 2Y19.85%
Revenue Next 3Y17.72%
Revenue Next 5Y15.34%
EBIT growth 1Y258.97%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year162.81%
EBIT Next 3Y59.8%
EBIT Next 5Y41.09%
FCF growth 1Y91.13%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y61.64%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%

UCB SA / UNC.DE FAQ

Can you provide the ChartMill fundamental rating for UCB SA?

ChartMill assigns a fundamental rating of 6 / 10 to UNC.DE.


What is the valuation status of UCB SA (UNC.DE) stock?

ChartMill assigns a valuation rating of 3 / 10 to UCB SA (UNC.DE). This can be considered as Overvalued.


Can you provide the profitability details for UCB SA?

UCB SA (UNC.DE) has a profitability rating of 6 / 10.


What is the valuation of UCB SA based on its PE and PB ratios?

The Price/Earnings (PE) ratio for UCB SA (UNC.DE) is 41.95 and the Price/Book (PB) ratio is 5.41.


Can you provide the financial health for UNC stock?

The financial health rating of UCB SA (UNC.DE) is 7 / 10.